sapunifiram has been researched along with Amnesia* in 3 studies
3 other study(ies) available for sapunifiram and Amnesia
| Article | Year |
|---|---|
Influence of ring size on the cognition-enhancing activity of DM235 and MN19, two potent nootropic drugs.
A series of analogs of DM235 and MN19, characterized by rings with different size, have been prepared and evaluated for their nootropic activity in the mouse passive-avoidance test. It was found that the optimal ring size for the analogs of DM235, showing endocyclic both amidic groups, is 6 or 7 atoms. For the compounds structurally related to MN19, carrying an exocyclic amide group, the piperidine ring is the moiety which gives the most interesting compounds. Topics: Adjuvants, Anesthesia; Amnesia; Animals; Avoidance Learning; Cognition; Drug Design; Mice; Nootropic Agents; Piperazines; Scopolamine; Structure-Activity Relationship; Sulfonamides | 2012 |
Synthesis and biological evaluation of 3,7-diazabicyclo[4.3.0]nonan-8-ones as potential nootropic and analgesic drugs.
A series of cis and trans 3,7-diazabicyclo[4.3.0]nonan-8-ones has been synthesized and tested for their ability to revert scopolamine-induced amnesia in the mouse passive-avoidance test. The racemates of the most potent compounds 4 and 7 were separated and tested, but no enantioselectivity was found for the nootropic activity. Compounds 4 and 7 and their enantiomers displayed interesting antihyperalgesic activity in two models of neuropathic pain (streptozotocin-induced and oxalilplatin-induced neuropathy) in comparison with pregabalin. Topics: Amnesia; Analgesics; Animals; Behavior, Animal; Drug Design; Ketones; Mice; Nootropic Agents; Scopolamine; Stereoisomerism | 2011 |
4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs.
Extrusion of one of the nitrogens of the piperazine ring of potent nootropic drugs previously described gave 4-aminopiperidine analogues that maintained high cognition enhancing activity in the mouse passive avoidance test. One of the new compounds (9, active at 0.01 mg/kg ip) may represent a new lead for the development of cognition enhancers useful to treat the cognitive deficit produced by neurodegenerative pathologies like Alzheimer's disease. Topics: Amnesia; Animals; Avoidance Learning; Chemical Phenomena; Chemistry, Physical; Cognition; Dose-Response Relationship, Drug; Indicators and Reagents; Mice; Muscarinic Antagonists; Neurodegenerative Diseases; Nootropic Agents; Piperidines; Receptors, AMPA; Scopolamine; Structure-Activity Relationship | 2003 |